Bioton S.A. (BIO) - Total Assets
Based on the latest financial reports, Bioton S.A. (BIO) holds total assets worth zł764.56 Million PLN (≈ $210.42 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BIO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Bioton S.A. - Total Assets Trend (2005–2025)
This chart illustrates how Bioton S.A.'s total assets have evolved over time, based on quarterly financial data. See BIO total equity for net asset value and shareholders' equity analysis.
Bioton S.A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Bioton S.A.'s total assets of zł764.56 Million consist of 19.0% current assets and 81.0% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 1.1% |
| Accounts Receivable | zł29.18 Million | 3.8% |
| Inventory | zł94.91 Million | 12.4% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł327.06 Million | 42.8% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Bioton S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bioton S.A. market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioton S.A.'s current assets represent 19.0% of total assets in 2025, a decrease from 44.5% in 2005.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2025, down from 3.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 14.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 42.8% of total assets.
Bioton S.A. Competitors by Total Assets
Key competitors of Bioton S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Bioton S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.08 | 0.96 |
| Quick Ratio | 0.49 | 0.33 | 0.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł42.19 Million | zł10.88 Million | zł-6.06 Million |
Bioton S.A. - Advanced Valuation Insights
This section examines the relationship between Bioton S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.60 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | zł764.56 Million |
| Market Capitalization | $90.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioton S.A.'s assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bioton S.A.'s assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bioton S.A. (2005–2025)
The table below shows the annual total assets of Bioton S.A. from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł764.56 Million ≈ $210.42 Million |
-3.72% |
| 2024-12-31 | zł794.14 Million ≈ $218.56 Million |
-3.42% |
| 2023-12-31 | zł822.22 Million ≈ $226.29 Million |
+1.47% |
| 2022-12-31 | zł810.33 Million ≈ $223.01 Million |
-6.34% |
| 2021-12-31 | zł865.19 Million ≈ $238.11 Million |
-0.22% |
| 2020-12-31 | zł867.11 Million ≈ $238.64 Million |
-1.62% |
| 2019-12-31 | zł881.42 Million ≈ $242.58 Million |
-12.73% |
| 2018-12-31 | zł1.01 Billion ≈ $277.97 Million |
-11.55% |
| 2017-12-31 | zł1.14 Billion ≈ $314.29 Million |
-11.83% |
| 2016-12-31 | zł1.30 Billion ≈ $356.45 Million |
+3.61% |
| 2015-12-31 | zł1.25 Billion ≈ $344.03 Million |
-36.02% |
| 2014-12-31 | zł1.95 Billion ≈ $537.74 Million |
+3.34% |
| 2013-12-31 | zł1.89 Billion ≈ $520.37 Million |
-1.28% |
| 2012-12-31 | zł1.92 Billion ≈ $527.12 Million |
-5.40% |
| 2011-12-31 | zł2.02 Billion ≈ $557.19 Million |
+28.00% |
| 2010-12-31 | zł1.58 Billion ≈ $435.30 Million |
-1.44% |
| 2009-12-31 | zł1.60 Billion ≈ $441.67 Million |
-22.28% |
| 2008-12-31 | zł2.06 Billion ≈ $568.26 Million |
+33.54% |
| 2007-12-31 | zł1.55 Billion ≈ $425.52 Million |
+55.92% |
| 2006-12-31 | zł991.63 Million ≈ $272.91 Million |
+176.90% |
| 2005-12-31 | zł358.12 Million ≈ $98.56 Million |
-- |
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more